Loading...
First-line immunotherapy with ipilimumab and nivolumab is the first new standard of care for mesothelioma since the introduction of pemetrexed in 2004. However, not all patients benefit, and there is interest in development of chemoimmunotherapy regimens. In an international, open-label, randomized, phase 3 trial, researchers evaluated platinum plus pemetrexed chemotherapy with or without pembrolizumab in 440 patients with untreated, unresectable, advanced pleural mesothelioma. Patients were stratified by histologic subtype before randomization; chemotherapy was given for up to 6 cycles, pembrolizumab for up to 2 years.
At a median follow-up of 16.2 months, overall survival (OS) was longer with pembrolizumab than with chemotherapy alone (med…